Marinus Pharmaceuticals, Inc.

LSE:0JYL Stock Report

Market Cap: US$17.0m

Marinus Pharmaceuticals Management

Management criteria checks 2/4

Marinus Pharmaceuticals' CEO is Scott Braunstein, appointed in Aug 2019, has a tenure of 5.25 years. total yearly compensation is $3.21M, comprised of 20.2% salary and 79.8% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $36.69K. The average tenure of the management team and the board of directors is 4 years and 4.6 years respectively.

Key information

Scott Braunstein

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage20.2%
CEO tenure5.3yrs
CEO ownership0.2%
Management average tenure4yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Scott Braunstein's remuneration changed compared to Marinus Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$140m

Jun 30 2024n/an/a

-US$149m

Mar 31 2024n/an/a

-US$145m

Dec 31 2023US$3mUS$650k

-US$141m

Sep 30 2023n/an/a

-US$134m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$35m

Dec 31 2022US$3mUS$591k

-US$20m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$4mUS$574k

-US$99m

Sep 30 2021n/an/a

-US$88m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$76m

Dec 31 2020US$4mUS$556k

-US$76m

Sep 30 2020n/an/a

-US$74m

Jun 30 2020n/an/a

-US$72m

Mar 31 2020n/an/a

-US$69m

Dec 31 2019US$2mUS$305k

-US$54m

Sep 30 2019n/an/a

-US$49m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$43m

Dec 31 2018US$210kn/a

-US$37m

Compensation vs Market: Scott's total compensation ($USD3.21M) is above average for companies of similar size in the UK market ($USD356.13K).

Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.

CEO

Scott Braunstein (61 yo)

5.3yrs

Tenure

US$3,214,100

Compensation

Dr. Scott N. Braunstein, M.D., has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He serves as an Independent Director at Caribou Biosciences, Inc. since June 2021. He...

Leadership Team

NamePositionTenureCompensationOwnership
Scott Braunstein
CEO, President & Chairman5.3yrsUS$3.21m0.22%
$ 36.7k
Steven Pfanstiel
COO, CFO & Treasurer3.6yrsUS$1.44m0.031%
$ 5.3k
Joseph Hulihan
Chief Medical Officer5.1yrsUS$1.37m0.031%
$ 5.3k
Alex Aimetti
Chief Scientific Officerno datano datano data
Sonya Weigle
Senior VP of Investor Relations1.4yrsno datano data
Martha Manning
Senior VP4.4yrsno data0.022%
$ 3.8k
Molly Cameron
Director of Corporate Communications & Investor Relations1.4yrsno datano data
Kimberly McCormick
Chief Regulatory & Quality Assurance Officerno datano datano data
Christina Shafer
Chief Commercial Officer4yrsno data0.034%
$ 5.8k
David Czekai
Chief Chemistryno datano datano data

4.0yrs

Average Tenure

61yo

Average Age

Experienced Management: 0JYL's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Scott Braunstein
CEO, President & Chairman6.2yrsUS$3.21m0.22%
$ 36.7k
Timothy Mayleben
Lead Independent Director15.9yrsUS$202.52k0.025%
$ 4.3k
Elan Ezickson
Independent Director4.9yrsUS$162.52k0.010%
$ 1.7k
Jacqueline A. French
Member of Scientific Advisory Boardno datano datano data
Seth H. Fischer
Independent Director8.2yrsUS$160.02k0.011%
$ 1.9k
Saraswathy Nochur
Independent Director3.7yrsUS$154.74k0.012%
$ 2.0k
Michael Rogawski
Member of Scientific Advisory Boardno datano datano data
Charles Austin
Independent Director4.3yrsUS$157.52k0.0096%
$ 1.6k
Christine Silverstein
Independent Director1.8yrsUS$249.21kno data
Marvin Johnson
Independent Director1.6yrsUS$304.81k0.0044%
$ 739.7
Eugen Trinka
Member of Scientific Advisory Boardno datano datano data
Elia M. Knight
Member of Scientific Advisory Boardno datano datano data

4.6yrs

Average Tenure

61.5yo

Average Age

Experienced Board: 0JYL's board of directors are considered experienced (4.6 years average tenure).